PharMerica A.I CyberSecurity Scoring
04/04/2026
Access Monitoring Plan
Access Monitoring Plan
No incidents recorded for PharMerica in 2026.
No incidents recorded for PharMerica in 2026.
No incidents recorded for PharMerica in 2026.
Fundada há mais de 60 anos e com capital 100% nacional, a EMS é a líder do mercado farmacêutico brasileiro há 19 anos consecutivos, pertencente ao Grupo NC, um dos maiores conglomerados brasileiros. A empresa ocupa também a liderança no segmento de genéricos desde 2013 (IQVIA 2019) e está entre os maiores laboratórios em preferência prescritiva no Brasil. Tem forte presença em PDVs de todo o país e atuação nas áreas de Prescrição Médica, Genéricos, Marcas, OTC e Hospitalar, fabricando medicamentos para praticamente todas as especialidades da Medicina. Possui fábricas em Hortolândia (SP), Manaus (AM), Brasília (DF) e Jaguariúna (SP). A EMS apoia ações de responsabilidade social dentro e fora do Brasil. Em 2017, por exemplo, o laboratório fechou parceria com a Organização Mundial da Saúde (OMS) para doar 100% do medicamento para erradicar, nos próximos anos, em todo o planeta, a bouba, doença negligenciada. A EMS é a única farmacêutica no mundo a ter abraçado essa causa. O Centro de Pesquisa & Desenvolvimento da EMS no Brasil é o mais moderno da América Latina. Na Itália, a EMS tem o laboratório de pesquisas MonteResearch. O foco de atuação do laboratório é a inovação nas seguintes frentes: inovação incremental; genéricos de alta complexidade; medicamentos biotecnológicos, por meio da empresa Bionovis; e inovação disruptiva, por meio da Brace Pharma, empresa da EMS instalada em 2013 nos Estados Unidos. Ainda, nos EUA, por meio de sua controlada Vero Biotech, localizada em Atlanta, Geórgia, a EMS, recentemente, obteve a aprovação de seu primeiro produto revolucionário submetido à FDA (Food and Drug Administration), posicionando o laboratório como uma empresa de inovação no mercado global. Com aportes frequentes em infraestrutura fabril e em pesquisa de ponta para desenvolver produtos inovadores, eficazes e seguros, a EMS, que já exporta para mais de 40 países, está preparada para continuar cuidando das pessoas que querem viver cada vez mais e melhor.
Lonza is a pioneer and world leader in the CDMO industry, setting the pace with cutting-edge science, smart technology, and lean manufacturing. United by a common purpose, we turn our customers’ breakthrough innovations into viable therapies and manufacture the medicines of tomorrow. Founded in Switzerland in 1897, our company is the first and original CDMO, and today we are more dynamic, agile and forward-focused than ever before. As one of the largest Western CDMOs, we bring together a global team of around 18,500 colleagues across five continents to deliver comprehensive, integrated solutions for our customers' complex needs. For our customers and their patients, we bring quality, safety and reliability to bring life-enhancing and life-saving treatments to market at speed and at scale. For our colleagues, we strive to create a sense of belonging and inclusion where every person can thrive and bring their best.
At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.merck.com. This site is intended for residents of the United States and Canada and their territories only. FLS: http://merck.us/3TKXNuZ
Established in 1984, we are a global pharmaceutical company headquartered in Hyderabad, India. Driven by our purpose of ‘Good Health Can’t Wait’, we work to provide access to affordable and innovative medicines. We offer a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Our major markets include USA, India, Russia & CIS countries, China, Brazil and Europe. As a company with a history of deep science that has led to several industry firsts, we continue to plan ahead and invest in future growth drivers such as access to novel molecules, digital therapeutics and consumer healthcare. As an early adopter of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance. For more information, log on to: www.drreddys.com. Caution Notice: Dr. Reddy's has been made aware of candidates receiving fraudulent job opportunities from unauthorised recruiting agencies or people impersonating Dr. Reddy's leaders. These fraudulent jobs may be advertised on employment sites or mimic our careers site and company email addresses. Please know that Dr. Reddy's Laboratories has no affiliation or connection to these situations. Dr. Reddy's (and its associated/group companies) follows a formal recruitment process through its own HR department. Please report immediately in case you suspect a fraudulent job. You may raise your concern by: Accessing https://drreddys.ethicspoint.com. Calling on the hotline number. List of hotline numbers are available in https://drreddys.ethicspoint.com. The hotline is available 24x7 in multiple languages. Writing to [email protected] or [email protected]. For our community guidelines on LinkedIn, please visit: https://shorturl.at/LTvNZ
Glenmark Pharmaceuticals Limited is a research-led, global organization committed to enriching lives. Innovation is deeply embedded in Glenmark’s culture; it is how we differentiate ourselves in our key markets and create greater value for our stakeholders. In our journey of innovation over the past four and a half decades, we have evolved from a generics company to a global organization offering specialty and branded products. Glenmark’s core values of Achievement, Respect, and Knowledge impart a sense of organizational unity that drives our growth. We have established a robust global branded generics, specialty, and OTC business; with a significant presence in the therapy areas of dermatology, respiratory, and oncology. Our ten state-of-the-art manufacturing facilities spread across four continents with operations in over 80 countries help us impact millions of patients across the globe. We recently consolidated our innovation efforts in small molecules and biologics research with the formation of ‘Ichnos Glenmark Innovation’ (IGI). This alliance is aimed at leveraging the capabilities of Glenmark and its subsidiary, Ichnos Sciences, to accelerate innovation in cancer treatment. To know more about IGI, check out: https://iginnovate.com/ Sustainability is an integral aspect of all our operations and we are focused on achieving our Environment, Social and Governance (ESG) goals. Our responsibility also extends to our communities, and over the years, our CSR efforts have touched the lives of over 3 million people.
As a global healthcare company, Fresenius Kabi is Committed to Life. The company’s products, technologies, and services are used for the therapy and care of critically and chronically ill patients. With over 41,000 employees and present in over 100 countries, Fresenius Kabi’s expansive product portfolio focuses on providing access to high-quality and lifesaving medicines and technologies. In Biopharma, Fresenius Kabi offers cutting-edge biosimilars for autoimmune diseases and oncology. With leading market positions in Clinical Nutrition, a broad portfolio of enteral and parenteral products makes a distinct difference in patients’ nutritional status. In MedTech, the company provides vital infusion pumps, cell and gene therapy devices, disposables, and more. Fresenius Kabi is the global leader in supplying blood collection bags and devices, supporting blood banks and healthcare facilities worldwide. The company’s I.V. Generics and Fluids for infusion therapy help save millions of lives every year, in emergency medicine, surgery, oncology, and intensive care. Fresenius Kabi takes a holistic approach to healthcare and uniquely combines experience, expertise, innovation, and dedication – making a difference in the lives of 450 million patients annually. With the #FutureFresenius strategy, the company is developing, producing, and selling new products and technologies and aspires to expand its position as a leading global provider of therapies, improve patient care, generate sustainable value for stakeholders – shaping the future of healthcare. Fresenius Kabi is an operating company of the Fresenius Group, founded in 1912, along with Helios and Quirónsalud. As ONE team, the companies in the Fresenius Group are committed to providing lifesaving and life-changing healthcare solutions on a global scale. User information & community guidelines: https://www.fresenius-kabi.com/social-media-terms-conditions Imprint: www.fresenius-kabi.com/imprint
Aurobindo Pharma Limited (NSE: AUROPHARMA, BSE: 524804, Reuters: ARBN.NS, Bloomberg: ARBP IN) is an integrated global pharmaceutical company headquartered in Hyderabad, India. The Company develops, manufactures, and markets a wide range of generic pharmaceuticals, branded specialty drugs, and active pharmaceutical ingredients (APIs) across more than 150 countries. It is ranked among the top 10 generic companies in eight European nations and holds the distinction of being the largest generic pharmaceutical company in the United States. With over 30 state-of-the-art manufacturing and packaging facilities approved by leading global regulatory authorities including USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, and Brazil ANVISA, Aurobindo Pharma ensures the highest standards of quality. Its robust portfolio spans eight major therapeutic areas: Central Nervous System (CNS), Antiretroviral (ARV), Cardiovascular (CVS), Antibiotics, Gastroenterology, Anti-diabetics, Oncology, and Dermatology, supported by a strong R&D infrastructure that drives innovation, affordability, and accessibility.
Established in 1907, Alembic Pharmaceuticals Limited is a leading pharmaceutical company in India. The Company is vertically integrated with the ability to develop, manufacture and market pharmaceutical products, pharmaceutical substances and Intermediates. Alembic is the market leader in the Macrolides segment of anti-infective drugs in India. Alembic's manufacturing facilities are located in Vadodara and Baddi in Himachal Pradesh. The plant at Vadodara has the largest fermentation capacity in India. The Panelav facility houses the API and formulation manufacturing (both US FDA approved) plants. The plant at Baddi, Himachal Pradesh manufactures formulations for the domestic and non-regulated export market. The company has a state of the art Research Centre at Vadodara.
Founded to serve health 70 years ago, Servier is a global pharmaceutical group governed by a non-profit Foundation that aspires to make a meaningful social impact for patients and for a sustainable world. The Group’s unique governance model preserves its independence and means it can fully serve its vocation of being committed to therapeutic progress to serve patient needs while adopting a long-term vision. Its employees are fully committed to this shared vocation, which serves as a source of inspiration every day. A world leader in cardiometabolism and venous diseases, Servier has made a major shift into oncology, which represents a new pillar of strategic growth. The Group devotes close to 70% of its R&D budget to this field, with the ambition of becoming a focused and innovative player in the development of treatments targeting rare cancers. Neurology will constitute a future growth driver. Servier is focusing on a limited number of diseases in this area where accurate patient profiling makes it possible to offer a targeted therapeutic response through precision medicine. To promote widespread access to quality care at a lower cost, the Group also offers a range of quality generic drugs covering most pathologies, leveraging well-known brands in France, and Eastern Europe. In all these areas, the Group takes patient considerations into account at every stage of the medicine life cycle. Headquartered in France, Servier relies on committed teams and strong geographical footprint; its medicines are available in close to 140 countries. In 2023/2024, the Group achieved sales revenue of €5.9 billion and EBITDA of €1.3 billion in 2024 (22.2%). Today, the Group employs over 22,000 people worldwide. -- To report a suspected adverse event with a Servier drug, please visit servier.com
Latest updates, reports, and threat intel affecting the global network.
AMERICANS can claim up to $10000 in a data breach settlement over a 2023 incident that compromised sensitive information. PharMerica, a...
Individuals who received notice of the PharMerica data breach may qualify to claim up to $10000 plus other benefits from a class action...
PharMerica has agreed to settle a class action lawsuit over a 2023 hacking incident and data breach that affected 5.8 million individuals.
Long-term care pharmacy network PharMerica suffered a data breach in 2023 that impacted more than 5.8 million individuals.
A federal judge has preliminarily approved a $5.3 million settlement related to a 2023 data breach that compromised the personal information...
Ransomware attacks cost manufacturing $17bn in downtime since 2018, with $1.9m daily losses, according to Comparitech.
The hack at UnitedHealth Group's tech unit potentially compromised a third of Americans' data, including U.S. military members' data,...
Relatives are being alerted that a PharMerica compromise exposed the sensitive data of their deceased loved ones, which could be used for identity theft.
A class-action lawsuit filed against one of the largest pharmacy companies serving US nursing homes and other institutions alleges the company failed to notify...
An incomplete patch for CVE-2026-18556 allows for authentication bypass and account takeover in N-central Versions through 2026.3.1
The OCPP 1.6 client in subsys/net/lib/ocpp parsed inbound WAMP RPC frames in parse_rpc_msg() (subsys/net/lib/ocpp/ocpp_j.c) using a hand-rolled helper, extract_string_field(), that copied the message's uid and action fields with strncpy(out_buf, token + 1, outlen - 1) and then scanned the result with strchr(out_buf, '"'). Because strncpy does not NUL-terminate the destination when the source is at least outlen - 1 (127) bytes long, the subsequent strchr reads past the 128-byte destination buffer into adjacent stack memory; if a " byte is found beyond the buffer, a one-byte out-of-bounds NUL write also occurs. A related defect in extract_payload() runs strchr/strrchr over the receive buffer, which may not be NUL-terminated when a maximal-length frame fills it. The parsed bytes come directly from the OCPP central-system server over a websocket: the reader thread fills recv_buf via websocket_recv_msg() and calls parse_rpc_msg() on each inbound DATA frame (subsys/net/lib/ocpp/ocpp.c). A malicious or compromised central server, or an on-path attacker (OCPP is commonly deployed over plain ws://), can send an RPC frame whose uid or action field is 127+ bytes with no closing quote, triggering the out-of-bounds access. The primary impact is a remotely triggerable denial of service: the unbounded scan can fault on an unmapped page, and the stray NUL write can corrupt adjacent stack state. The over-read data is not reflected to the peer, so disclosure is limited. The feature is EXPERIMENTAL and must be explicitly enabled (CONFIG_OCPP). The fix replaces the manual parser with the bounds-respecting json_mixed_arr_parse() and copies the extracted uid with an explicitly NUL-terminated buffer, eliminating both over-reads.
A vulnerability in huggingface/transformers versions <=5.8.0.dev0 allows an attacker to perform arbitrary file writes via path traversal. The issue resides in the `save_pretrained()` methods of `PreTrainedTokenizerBase` and `ProcessorMixin`, where keys from the `chat_template` dictionary are used directly as filenames without proper validation. An attacker can exploit this by publishing a malicious Hugging Face Hub repository with a crafted `tokenizer_config.json` file. When a victim downloads and saves the tokenizer or processor, the attacker-controlled keys can escape the intended save directory, enabling arbitrary file writes with attacker-controlled content. This vulnerability affects multiple processors inheriting from `ProcessorMixin`, including Idefics, Florence, Gemma, Phi, and Qwen-VL.
PyAthena prior to 3.35.4 contains a sql injection vulnerability that allows unauthenticated attackers to inject arbitrary SQL by exploiting improper quote-escaping in DefaultParameterFormatter.format(), which routes DELETE and CTAS statements to the _escape_hive function that backslash-escapes single quotes rather than doubling them. Because Athena and Trino do not treat backslashes as escape characters inside string literals, attacker-supplied input such as a single quote followed by SQL syntax causes the parser to terminate the string literal prematurely, enabling data exfiltration via UNION SELECT, execution of destructive statements, and attacker-controlled CTAS destination and content.
Zephyr's Bluetooth Mesh subnet key management leaks one PSA Crypto key slot on every subnet-key teardown. In subsys/bluetooth/mesh/subnet.c, net_keys_create() imports the Private Beacon Key into a PSA key slot under CONFIG_BT_MESH_PRIV_BEACONS (enabled by default), but subnet_keys_destroy() guarded the matching psa_destroy_key() with CONFIG_BT_MESH_V1d1. That Kconfig symbol was removed when explicit Mesh 1.0.1 support was dropped, so the destroy branch became permanently dead code and the import is never balanced by a destroy. The imbalanced teardown is reached every time subnet keys are destroyed: deleting a subnet (Config Server NetKey Delete), completing a Key Refresh Procedure (which retires the old key set), and resetting/re-provisioning the node. The over-the-air triggers are processed only under the node's device key, so they are exercisable by the provisioner or network administrator that owns the node, reachable over the Bluetooth Mesh network. With the default CONFIG_MBEDTLS_PSA_KEY_SLOT_COUNT of 16, repeated add/delete or key-refresh cycles exhaust the shared PSA key-slot pool after roughly a dozen rounds. Once exhausted, bt_mesh_private_beacon_key() and thus subnet creation fail: the node can no longer add subnets or complete key refresh, and other PSA crypto consumers on the device may be starved, until the device is rebooted. The fix aligns the destroy guard with the import guard (CONFIG_BT_MESH_PRIV_BEACONS) so each slot is freed.
curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'
Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.
Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.